Oncolytics Biotech Inc trades with the ticker ONC on the TSX and is in the Biotechnology industry.
Overview
Oncolytics Biotech Inc., a development-stage biopharmaceutical company, focuses on the discovery and development of pharmaceutical products for the treatment of cancer. The company is developing pelareorep, an intravenously delivered immunotherapeutic agent, which is in phase 3 clinical trial for the treatment of hormone receptor-positive / human epidermal growth factor 2-negative metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma. Oncolytics Biotech Inc. has a co-development agreement with Merck KGaA and Pfizer Inc. to co-develop pelareorep in combination with paclitaxel and Bavencio, a human anti-PD-L1 antibody for the treatment of hormone receptor-positive/human epidermal growth factor 2-negative metastatic breast cancer. The company was incorporated in 1998 and is headquartered in Calgary, Canada.
Looking to invest in Oncolytics Biotech Inc? Our analysis brings in the key facts, competitor research and valuation metrics for you to make an informed decision.
Table of Contents
show
ONC.TO Stock Price and Key Stats
ETF Key Stats
Exchange: TSX
Market Cap : $105.682MM
PE Ratio:
Price: 19.1 (Updated: 3/12/2024 0:47:16)
Oncolytics Biotech Inc (ONC) vs Competitors in Biotechnology
Lets see how ONC.TO stacks up against others in the Biotechnology asset management industry. We have identified its main peers as:Aeterna Zentaris Inc, Aptose Biosciences Inc, BELLUS Health Inc, Fennec Pharmaceuticals Inc, IMV Inc
.Biotechnology Industry Comparisons
| Company | Market Cap ($MM) | P/E Ratio | EV/EBITDA | Dividend Yield |
|---|---|---|---|---|
| Aeterna Zentaris Inc (AEZS) | $12.674 | N/A | 1.709 | N/A% |
| Aptose Biosciences Inc (APS) | $33.927 | N/A | -0.231 | N/A% |
| BELLUS Health Inc (BLU) | $2,470.298 | N/A | -16.428 | 0.0% |
| Fennec Pharmaceuticals Inc (FRX) | $352.565 | N/A | -21.793 | N/A% |
| IMV Inc (IMV) | $13.117 | N/A | -0.843 | 0.0% |
EV/EBITDA: Enterprise Value to Earnings Before Interest, Taxes, Depreciation, and Amortization – this ratio compares the value of a company, including debt, to the company’s cash earnings less non-cash expenses
Industry: companies that have a lot in common
Market Cap: Market Capitalization – the total value of all a corporation’s stock
N/A: Not Applicable or Not Available
P/E: Price-to-Earnings – this ratio relates a corporation’s share price to its earnings per share
Price: Stock Price – current value to buyers and sellers
Dividend Yield: Dividend or Distribution Yield
Comparisons within Biotechnology
- Oncolytics Biotech Inc (ONC) vs Aeterna Zentaris Inc (AEZS)
- ONC has higher EPS (-0.51 vs -6.47). AEZS and ONC both have P/E’s under 0.
- Oncolytics Biotech Inc (ONC) vs Aptose Biosciences Inc (APS)
- ONC has higher EPS (-0.51 vs -10.45). APS and ONC both have P/E’s under 0.
- Oncolytics Biotech Inc (ONC) vs BELLUS Health Inc (BLU)
- ONC has higher EPS (-0.51 vs -0.96). BLU provides dividends, while ONC does not. BLU and ONC both have P/E’s under 0.
- Oncolytics Biotech Inc (ONC) vs Fennec Pharmaceuticals Inc (FRX)
- ONC has higher EPS (-0.51 vs -1.01). FRX and ONC both have P/E’s under 0.
- Oncolytics Biotech Inc (ONC) vs IMV Inc (IMV)
- ONC has higher EPS (-0.51 vs -6.11). IMV provides dividends, while ONC does not. IMV and ONC both have P/E’s under 0.
Our Recommendation: Hold
Shows positive EPS growth from this year to next, suggesting improving profitability.
How to Buy ONC stock on the TSX
You can buy on pretty much any online brokerage in Canada, since it trades on the TSX. If you are looking for some easy options take a look at these two:| Image | Product Title | Features | Price |
|---|---|---|---|
Editor's Choice  |
| Get $25 Signup Bonus | |
Reliable Pick  |
| Get $50 Free Stock Trades |
